Describe the limitations of traditional D2-binding treatments for schizophrenia Assess the role of muscarinic acetylcholine receptor activation in schizophrenia, according to current neurobiological evidence Summarize the MOAs and latest efficacy, safety, and tolerability data associated withe merging muscarinic acetylcholine receptor activators for schizophrenia Evaluate the potential treatment implications associated with emerging muscarinic receptor activators for schizophrenia, including drug-drug interactions and risk/benefit discussions
- Provider:HMP Education
- Activity Link: https://hmpeducation.com/program/24-uspc-101-21
- Start Date: 2024-12-16 06:00:00
- End Date: 2024-12-16 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.25 hours
AMA PRA Category 1 Credit™️: 1.25 hours
Nursing: 1.25 hours
Pharmacy: 1.25 hours
Psychology: 1.25 hours
Social Work: 1.25 hours - MOC Credit Details: ABS - 1.25 Point; Credit Type(s): Accredited CME (ABS)
- Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: General Surgery
Subscribe
Login
0 Comments
Oldest